Abstract
Under the backdrop of the Maritime Silk Road Initiative, the study on the international development of China’s marine biopharmaceutical industry based on factor allocation is of great practical significance for industrial sustainability and building the industry into a leading international player in the global market. In this paper, we first identify the leading factors that influence the development of the marine biopharmaceutical industry, namely, resources, technologies, talents, investments and policies. Furthermore, the hierarchical structure model of these factors was established and analyzed using the analytic hierarchy process (AHP). The importance ranking of these constraints was identified, as follows: technologies > talents > resources > policies > investments. Then, based on the theory of comparative advantage and game theory, we analyzed the necessity of China’s marine biopharmaceutical industry going global, that is, international cooperation may lay a solid foundation for the win-win outcome of this industry in countries along the Maritime Silk Road. According to the status quo of China’s marine biopharmaceutical industry, based on these findings, an international factor–allocation cooperation path was designed, and the path chart of the international development of the marine biopharmaceutical industry was drawn. Finally, methods for the development of China’s marine biopharmaceutical industry were proposed, which covers efforts to protect marine resources, promote R&D for core technologies, establish a strong talent pool, encourage more investments, provide policy support and promote worldwide cooperation. It is the first report to investigate the path of the sustainable exploitation of the marine biopharmaceutical industry from the perspective of factor allocation amidst the backdrop of the Maritime Silk Road Initiative.
Highlights
As early as the Qin and Han Dynasties, the Maritime Silk Road to a large extent made up for the limitations of the Continental Silk Road in a way that extended cultural exchanges to the sea
This study is the first report to investigate the sustainable exploitation of marine biopharmaceutical industry based on factor allocation under the backdrop of the Maritime Silk Road Initiative
Amidst the Maritime Silk Road Initiative, according to the status quo of China’s marine biopharmaceutical industry, the present study investigates the factors allocation of the development of the marine biopharmaceutical industry in China by using analytic hierarchy process (AHP), the comparative advantage theory, and game theory
Summary
As early as the Qin and Han Dynasties, the Maritime Silk Road to a large extent made up for the limitations of the Continental Silk Road in a way that extended cultural exchanges to the sea. Focused on strategic partnerships between China and the countries from Association of Southeast Asian Nations (ASEAN), the 21st Century Maritime Silk Road Initiative promotes regional economic cooperation to strategically support the development of marine industries, the marine biopharmaceutical industry. Based on the above analysis, it could be concluded that China and the countries along the Maritime Silk Road have obvious comparative advantages in the marine biopharmaceutical industry, which are mainly characterized by China’s advantages in R&D technologies, capital investments and professional talents, and being alongside countries with marine medicinal bioresources. While utilizing the rich marine medicinal bioresources in countries along the Maritime Silk Road for thorough diverse researches, China occupies a lot of market share and promotes the common development of medicine R&D in ways that obtain additional benefits. The alongside countries profits come from China’s technological sharing, special investment, talents transfer and training in ways that make them more competitive in higher levels
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
